Nebivolol: A Comprehensive Pharmacological Review of a Third-Generation Cardioselective Beta-Blocker with Nitric Oxide-Mediated Vasodilatory Properties

Nebivolol represents a distinctive pharmacological agent within the beta-adrenergic receptor antagonist class, distinguished by its dual mechanism of action combining highly selective beta-1 receptor blockade with nitric oxide-mediated vasodilation. This comprehensive review examines nebivolol's clinical pharmacology, encompassing its FDA-approved indication for hypertension management, evolving off-label applications, and nuanced pharmacokinetic profile. The medication demonstrates unique cardioselectivity that is dose-dependent and influenced by CYP2D6 metabolic status, with favorable tolerability in patients with pulmonary disease. Nebivolol's capacity to stimulate endothelial nitric oxide synthase via beta-3 agonism confers additional therapeutic advantages, particularly in populations with endothelial dysfunction such as those with diabetes mellitus, erectile dysfunction, and vascular disease. The drug's pharmacokinetics reveal complex hepatic metabolism through glucuronidation and CYP2D6 pathways, with active metabolites contributing to sustained beta-blocking activity. Clinical considerations including dosing strategies, special population adjustments, drug interactions, and monitoring parameters are critically evaluated. The safety profile, while generally favorable, warrants attention to potential adverse effects and contraindications. This review synthesizes current evidence to provide healthcare professionals with a comprehensive understanding of nebivolol's role in contemporary cardiovascular therapeutics, emphasizing the importance of interprofessional collaboration in optimizing patient outcomes.